5-fluorouracil + cyclophosphamide + mitoxantrone + vindesine

This is a combination chemotherapy regimen consisting of four cytotoxic agents: 5-fluorouracil, cyclophosphamide, mitoxantrone, and vindesine. Each drug has a distinct mechanism of action targeting cancer cell proliferation and survival. - **5-fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and repair. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands, leading to apoptosis in rapidly dividing cells. - **Mitoxantrone** is an anthracenedione that intercalates into DNA and inhibits topoisomerase II, causing double-strand breaks in DNA. - **Vindesine** is a vinca alkaloid that binds to tubulin and disrupts microtubule assembly, inhibiting mitosis. This combination has been explored for the treatment of advanced or metastatic cancers (notably breast cancer), leveraging the complementary mechanisms of each component to maximize antitumor efficacy while attempting to manage resistance or toxicity seen with single-agent therapy[4]. While similar regimens (such as CNF—cyclophosphamide, mitoxantrone, 5-fluorouracil) have been studied in clinical trials for advanced breast cancer[4], the addition of vindesine represents further intensification with another class of cytotoxic agent.